Continuous Small-Dose Aprotinin Controls Fibrinolysis during Orthotopic Liver Transplantation

Randy J. Marcel, William C. Stegall, C. Tracy Suit, John C. Arnold, Richard L. Vera, Michael A E Ramsay, Michael B. O'Donnell, Thomas H. Swygert, H. A. Tillmann Hein, Charles W. Whitten

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Large doses of aprotinin (1,000,000-2,000,000 kallikrein inhibitor units [KIU] initial dose and a 500,000 KIU/h infusion) have been used during orthotopic liver transplantation (OLT) to reduce the incidence and severity of fibrinolysis. This double-blinded study was designed to investigate whether a small-dose infusion of aprotinin (200,000 KIU/h) would control fibrinolysis. A controlled study was undertaken to compare small-dose aprotinin with a placebo in patients undergoing OLT with veno-venous bypass. Forty-four patients were randomized either to the aprotinin group (n = 21), which received an intravenous infusion of 200,000 KIU/h without an initial dose, or to a control group (n = 23), which received normal saline. Coagulation variables, thrombelastograms, and postoperative blood drainage were measured. Blood levels of fibrin degradation products (FDP) were significantly higher in the control group (95% > 20 μg/mL) at the end of surgery compared to the aprotinin group (53% > 20 μg/mL, P < 0.01). The transfusion of cryoprecipitate units was more in the control group versus the aprotinin (12.6 ± 12.8 vs 5.7 ± 7.5; P < 0.04), as was the number of fresh frozen plasma units (6.6 ± 3.5 vs 3.6 ± 6.1; P < 0.05). We conclude that an infusion of a small dose of aprotinin can safely control fibrinolysis during liver transplantation with a concomitant reduction in transfusion of blood products.

Original languageEnglish (US)
Pages (from-to)1122-1125
Number of pages4
JournalAnesthesia and Analgesia
Volume82
Issue number6
StatePublished - 1996

Fingerprint

Aprotinin
Fibrinolysis
Liver Transplantation
Kallikreins
Control Groups
Fibrin Fibrinogen Degradation Products
Intravenous Infusions
Blood Transfusion
Drainage
Placebos
Incidence

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Marcel, R. J., Stegall, W. C., Tracy Suit, C., Arnold, J. C., Vera, R. L., Ramsay, M. A. E., ... Whitten, C. W. (1996). Continuous Small-Dose Aprotinin Controls Fibrinolysis during Orthotopic Liver Transplantation. Anesthesia and Analgesia, 82(6), 1122-1125.

Continuous Small-Dose Aprotinin Controls Fibrinolysis during Orthotopic Liver Transplantation. / Marcel, Randy J.; Stegall, William C.; Tracy Suit, C.; Arnold, John C.; Vera, Richard L.; Ramsay, Michael A E; O'Donnell, Michael B.; Swygert, Thomas H.; Tillmann Hein, H. A.; Whitten, Charles W.

In: Anesthesia and Analgesia, Vol. 82, No. 6, 1996, p. 1122-1125.

Research output: Contribution to journalArticle

Marcel, RJ, Stegall, WC, Tracy Suit, C, Arnold, JC, Vera, RL, Ramsay, MAE, O'Donnell, MB, Swygert, TH, Tillmann Hein, HA & Whitten, CW 1996, 'Continuous Small-Dose Aprotinin Controls Fibrinolysis during Orthotopic Liver Transplantation', Anesthesia and Analgesia, vol. 82, no. 6, pp. 1122-1125.
Marcel RJ, Stegall WC, Tracy Suit C, Arnold JC, Vera RL, Ramsay MAE et al. Continuous Small-Dose Aprotinin Controls Fibrinolysis during Orthotopic Liver Transplantation. Anesthesia and Analgesia. 1996;82(6):1122-1125.
Marcel, Randy J. ; Stegall, William C. ; Tracy Suit, C. ; Arnold, John C. ; Vera, Richard L. ; Ramsay, Michael A E ; O'Donnell, Michael B. ; Swygert, Thomas H. ; Tillmann Hein, H. A. ; Whitten, Charles W. / Continuous Small-Dose Aprotinin Controls Fibrinolysis during Orthotopic Liver Transplantation. In: Anesthesia and Analgesia. 1996 ; Vol. 82, No. 6. pp. 1122-1125.
@article{d1bb543624934f8cb51923f823c589db,
title = "Continuous Small-Dose Aprotinin Controls Fibrinolysis during Orthotopic Liver Transplantation",
abstract = "Large doses of aprotinin (1,000,000-2,000,000 kallikrein inhibitor units [KIU] initial dose and a 500,000 KIU/h infusion) have been used during orthotopic liver transplantation (OLT) to reduce the incidence and severity of fibrinolysis. This double-blinded study was designed to investigate whether a small-dose infusion of aprotinin (200,000 KIU/h) would control fibrinolysis. A controlled study was undertaken to compare small-dose aprotinin with a placebo in patients undergoing OLT with veno-venous bypass. Forty-four patients were randomized either to the aprotinin group (n = 21), which received an intravenous infusion of 200,000 KIU/h without an initial dose, or to a control group (n = 23), which received normal saline. Coagulation variables, thrombelastograms, and postoperative blood drainage were measured. Blood levels of fibrin degradation products (FDP) were significantly higher in the control group (95{\%} > 20 μg/mL) at the end of surgery compared to the aprotinin group (53{\%} > 20 μg/mL, P < 0.01). The transfusion of cryoprecipitate units was more in the control group versus the aprotinin (12.6 ± 12.8 vs 5.7 ± 7.5; P < 0.04), as was the number of fresh frozen plasma units (6.6 ± 3.5 vs 3.6 ± 6.1; P < 0.05). We conclude that an infusion of a small dose of aprotinin can safely control fibrinolysis during liver transplantation with a concomitant reduction in transfusion of blood products.",
author = "Marcel, {Randy J.} and Stegall, {William C.} and {Tracy Suit}, C. and Arnold, {John C.} and Vera, {Richard L.} and Ramsay, {Michael A E} and O'Donnell, {Michael B.} and Swygert, {Thomas H.} and {Tillmann Hein}, {H. A.} and Whitten, {Charles W.}",
year = "1996",
language = "English (US)",
volume = "82",
pages = "1122--1125",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Continuous Small-Dose Aprotinin Controls Fibrinolysis during Orthotopic Liver Transplantation

AU - Marcel, Randy J.

AU - Stegall, William C.

AU - Tracy Suit, C.

AU - Arnold, John C.

AU - Vera, Richard L.

AU - Ramsay, Michael A E

AU - O'Donnell, Michael B.

AU - Swygert, Thomas H.

AU - Tillmann Hein, H. A.

AU - Whitten, Charles W.

PY - 1996

Y1 - 1996

N2 - Large doses of aprotinin (1,000,000-2,000,000 kallikrein inhibitor units [KIU] initial dose and a 500,000 KIU/h infusion) have been used during orthotopic liver transplantation (OLT) to reduce the incidence and severity of fibrinolysis. This double-blinded study was designed to investigate whether a small-dose infusion of aprotinin (200,000 KIU/h) would control fibrinolysis. A controlled study was undertaken to compare small-dose aprotinin with a placebo in patients undergoing OLT with veno-venous bypass. Forty-four patients were randomized either to the aprotinin group (n = 21), which received an intravenous infusion of 200,000 KIU/h without an initial dose, or to a control group (n = 23), which received normal saline. Coagulation variables, thrombelastograms, and postoperative blood drainage were measured. Blood levels of fibrin degradation products (FDP) were significantly higher in the control group (95% > 20 μg/mL) at the end of surgery compared to the aprotinin group (53% > 20 μg/mL, P < 0.01). The transfusion of cryoprecipitate units was more in the control group versus the aprotinin (12.6 ± 12.8 vs 5.7 ± 7.5; P < 0.04), as was the number of fresh frozen plasma units (6.6 ± 3.5 vs 3.6 ± 6.1; P < 0.05). We conclude that an infusion of a small dose of aprotinin can safely control fibrinolysis during liver transplantation with a concomitant reduction in transfusion of blood products.

AB - Large doses of aprotinin (1,000,000-2,000,000 kallikrein inhibitor units [KIU] initial dose and a 500,000 KIU/h infusion) have been used during orthotopic liver transplantation (OLT) to reduce the incidence and severity of fibrinolysis. This double-blinded study was designed to investigate whether a small-dose infusion of aprotinin (200,000 KIU/h) would control fibrinolysis. A controlled study was undertaken to compare small-dose aprotinin with a placebo in patients undergoing OLT with veno-venous bypass. Forty-four patients were randomized either to the aprotinin group (n = 21), which received an intravenous infusion of 200,000 KIU/h without an initial dose, or to a control group (n = 23), which received normal saline. Coagulation variables, thrombelastograms, and postoperative blood drainage were measured. Blood levels of fibrin degradation products (FDP) were significantly higher in the control group (95% > 20 μg/mL) at the end of surgery compared to the aprotinin group (53% > 20 μg/mL, P < 0.01). The transfusion of cryoprecipitate units was more in the control group versus the aprotinin (12.6 ± 12.8 vs 5.7 ± 7.5; P < 0.04), as was the number of fresh frozen plasma units (6.6 ± 3.5 vs 3.6 ± 6.1; P < 0.05). We conclude that an infusion of a small dose of aprotinin can safely control fibrinolysis during liver transplantation with a concomitant reduction in transfusion of blood products.

UR - http://www.scopus.com/inward/record.url?scp=0029995641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029995641&partnerID=8YFLogxK

M3 - Article

C2 - 8638778

AN - SCOPUS:0029995641

VL - 82

SP - 1122

EP - 1125

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 6

ER -